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Abstract
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a frequently disabling neuroinflammatory
syndrome with a relapsing course. Blood-based disease severity and prognostic biomarkers for NMOSD are a yet
unmet clinical need. Here, we evaluated serum glial fibrillary acidic protein (sGFAP) and neurofilament light (sNfL) as
disease severity and prognostic biomarkers in patients with aquaporin-4 immunoglobulin (Ig)G positive (AQP4-IgG+)
NMOSD.
Methods: sGFAP and sNfL were determined by single-molecule array technology in a prospective cohort of 33
AQP4-IgG+ patients with NMOSD, 32 of which were in clinical remission at study baseline. Sixteen myelin
oligodendrocyte glycoprotein IgG-positive (MOG-IgG+) patients and 38 healthy persons were included as controls.
Attacks were recorded in all AQP4-IgG+ patients over a median observation period of 4.25 years.
Results: In patients with AQP4-IgG+ NMOSD, median sGFAP (109.2 pg/ml) was non-significantly higher than in
MOG-IgG+ patients (81.1 pg/ml; p = 0.83) and healthy controls (67.7 pg/ml; p = 0.07); sNfL did not substantially
differ between groups. Yet, in AQP4-IgG+, but not MOG-IgG+ patients, higher sGFAP was associated with worse
clinical disability scores, including the Expanded Disability Status Scale (EDSS, standardized effect size = 1.30,
p = 0.007) and Multiple Sclerosis Functional Composite (MSFC, standardized effect size = − 1.28, p = 0.01). While in
AQP4-IgG+, but not MOG-IgG+ patients, baseline sGFAP and sNfL were positively associated (standardized effect size
= 2.24, p = 0.001), higher sNfL was only non-significantly associated with worse EDSS (standardized effect size =
1.09, p = 0.15) and MSFC (standardized effect size = − 1.75, p = 0.06) in patients with AQP4-IgG+ NMOSD. Patients
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with AQP4-IgG+ NMOSD with sGFAP > 90 pg/ml at baseline had a shorter time to a future attack than those with
sGFAP ≤ 90 pg/ml (adjusted hazard ratio [95% confidence interval] = 11.6 [1.3–105.6], p = 0.03). In contrast, baseline
sNfL levels above the 75th age adjusted percentile were not associated with a shorter time to a future attack in
patients with AQP4-IgG+ NMOSD.
Conclusion: These findings suggest a potential role for sGFAP as biomarker for disease severity and future disease
activity in patients with AQP4-IgG+ NMOSD in phases of clinical remission.
Keywords: Neuromyelitis optica spectrum disorder, Glial fibrillary acidic protein, Neurofilament light chain protein,
Aquaporin-4 immunoglobulin G, Myelin oligodendrocyte glycoprotein immunoglobulin G, Biomarker, Serum
Background
Neuromyelitis optica spectrum disorder (NMOSD) is a
severe neuroinflammatory syndrome primarily affecting
the optic nerves, spinal cord, and brainstem, with a re-
lapsing and frequently disabling course, that is difficult
to predict at the individual level [1, 2]. NMOSD is asso-
ciated with immunoglobulin (Ig)G autoantibodies
against the astrocytic water channel aquaporin-4
(AQP4-IgG) [3, 4]. AQP4-IgG causes an antibody-
mediated astrocytopathy, thereby playing a key role in
the immunopathogenesis of NMOSD [5, 6].
Current diagnosis of NMOSD is based on the Inter-
national Panel for NMO Diagnosis (IPND) criteria [7].
Among patients meeting the IPND criteria, ~ 75% have
AQP4-IgG [8]. Among the remaining AQP4-IgG sero-
negative patients, ~ 40% have IgG against myelin oligo-
dendrocyte glycoprotein (MOG-IgG), while ~ 60% are
AQP4-IgG/MOG-IgG double seronegative [8]. MOG-
IgG has been associated with inflammatory demyelin-
ation and defines a disease entity now termed MOG
antibody disease (MOGAD), whose clinical presentation
partially overlaps with NMOSD as defined by the IPND
criteria [6, 9–11]. However, whereas astrocytes are con-
sidered the primary autoantibody target in AQP4-IgG+
NMOSD, in MOGAD, oligodendrocytes are considered
the primary autoantibody target, as MOG is expressed
on oligodendrocytes [9, 11].
Given that relapse preventing treatment of AQP4-IgG+
NMOSD relies on immunotherapies with potentially
relevant side effects, blood-based biomarkers for disease
severity and future disease activity, that could help guid-
ing treatment decisions in patients with AQP4-IgG+
NMOSD, are a yet unmet clinical need. Glial fibrillary
acidic protein (GFAP) is an astrocytic intermediate fila-
ment [12], which is strongly elevated in cerebrospinal
fluid (CSF) during attacks of NMOSD [13–16]. Neurofil-
ament light chain protein (NfL) is a neuronal intermedi-
ate filament used as a biomarker for neuroaxonal
damage [17]. Single-molecule array (Simoa) technology
enables the ultrasensitive detection of both markers in
serum [18, 19]. Employing Simoa technology, two recent
studies, which each analyzed 33 patients with NMOSD,
observed elevated serum GFAP (sGFAP) levels in patients
with AQP4-IgG+ NMOSD, especially after recent attacks,
and an association of sGFAP with the Expanded Disability
Status Scale (EDSS), a clinical disability score [20, 21].
However, it is unclear whether those results, which were
obtained in patients with rather active disease (35% and
65% of patients, respectively, with a recent relapse) [20,
21], may also apply to clinically stable patients. Further-
more, the role of sGFAP and serum NfL (sNfL) as prog-
nostic biomarkers in patients with AQP4-IgG+ NMOSD
remains to be defined in prospective cohorts.
Here, we performed a detailed investigation of sGFAP
and sNfL as disease severity and prognostic biomarkers
in a well-characterized prospective cohort of 33 patients
with AQP4-IgG+ NMOSD. We also included MOG-
IgG+ patients (n = 16) as specificity controls as well as
healthy individuals (n = 38). AQP4-IgG+ patients were
followed over a median observation period of 4.25 years.
Altogether, the findings of this study suggest a potential
role of sGFAP as biomarker for disease severity and fu-
ture disease activity in patients with AQP4-IgG+
NMOSD in phases of clinical remission.
Methods
Participants
Patients were recruited at the Department of Neurology
and the NeuroCure Clinical Research Center, Charité –
Universitätsmedizin Berlin, between August 2015 and
March 2018 and participate in an ongoing prospective
longitudinal study of patients with NMOSD and related
disorders. Inclusion criteria for the present investigation
comprised age > 18 years, a diagnosis of AQP4-IgG+
NMOSD according to the 2015 IPND consensus criteria
[7], or a diagnosis of MOG-IgG associated encephalomy-
elitis (herein referred to as “MOG-IgG+ patients”) ac-
cording to the criteria of Jarius and colleagues [22]. All
patients included in this study were Caucasians. At the
baseline visit of the study, demographics and medical
history, including prior attacks, were obtained and all
patients underwent thorough neurological examination
with assessment of the EDSS [23] by a trained EDSS
rater. Additionally, the Timed 25-Foot Walk (T25-FW),
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9-Hole Peg Test (9-HPT), and Paced Auditory Serial
Addition Test (PASAT) with single digits every 3 s, com-
posing the Multiple Sclerosis Functional Composite
(MSFC) [24], were carried out. MSFC scores were calcu-
lated as previously described [25], using our cohort’s re-
spective baseline means and standard deviations for Z-
transformation. Patient sera were collected at the base-
line visit, processed according to standard operating pro-
cedures and stored at − 80 °C. Applying exactly the same
procedures, sera were collected from healthy controls
(HC) recruited among hospital staff. In patients with
NMOSD, all assessments and procedures were repeated
at yearly follow-up visits. Patients with a relapse within
≤ 90 days before the baseline visit were considered to
have active disease and patients with a relapse > 90 days
before the baseline visit were considered to be in clinical
remission.
Laboratory procedures
AQP4-IgG and MOG-IgG were determined in serum
using fixed cell-based assays (CBAs, Euroimmun,
Lübeck, Germany), in-house fixed CBAs (Sven Jarius,
University of Heidelberg, Germany) and in-house live
CBAs (Markus Reindl, Medical University Innsbruck,
Austria). Patients were classified as either AQP4-IgG+
or MOG-IgG+ if they had tested positive for AQP4-
IgG or MOG-IgG at least once during their disease
course. None of the patients were AQP4-IgG and
MOG-IgG double positive. Coded serum samples
were shipped on dry ice to the Department of Neur-
ology, University of Basel, Switzerland, where sGFAP
and sNfL were determined by Simoa (Quanterix, Lex-
ington, MA, USA) by operators blinded to clinical
data, as previously described [20, 26].
Statistical analyses
Non-normally distributed variables (sGFAP, sNfL, time
intervals, T25-FW) were log-transformed to meet the
normal distribution assumption for use in parametric
models. Differences of baseline sGFAP and sNFL in
women and men were assessed by Mann-Whitney tests,
and differences in sGFAP and sNfL between baseline
and follow up by Wilcoxon signed-rank test.
Further group comparisons and association analyses
were conducted using linear models, including age
and, where applicable, interval since last attack before
baseline as covariates. To provide comparable mea-
sures for the magnitude of investigated phenomena as
well as to account for the dependency of null hypoth-
esis significance tests on sample size, we calculated
standardized measures of effect sizes [27]. To assess
differences of baseline characteristics between groups
(Table 1), we calculated absolute standardized mean
difference values (SMD; R packages “tableone”). For
association analyses, we calculated adjusted standard-
ized effect sizes (SES; R package “emmeans”). Both
SMD and SES are derived from mean differences in
relation to the common standard deviation. Values of
SMD or SES > 0.8 or < − 0.8 were considered as
meaningful effect sizes, irrespective of the correspond-
ing p value [28]. Accordingly, associations with an
SES > 0.8 or < − 0.8 and a p value > 0.05 are reported
as “non-significant associations.”
To assess inter group differences of associations be-
tween sGFAP or sNFL and other parameters, interaction
analyses were conducted [29]. To this end, the group
variable and an interaction term of log-transformed
baseline sGFAP or sNfL by group were additionally in-
cluded in the model. Results of these analyses are re-
ported as partial eta squared (ηp
2; R package
“effectsize”), an adjusted measure of the size of the inter-
action effect, together with the respective p values.
Time to first attack was modeled using Cox proportional
hazards regression. For Cox regression analyses, the obser-
vation period was calculated from the last attack prior to
baseline. Cox regression analyses were adjusted for age and
the interval between baseline visit and last prior attack. For
Cox regression analyses, sNfL concentrations were con-
verted into age adjusted sNfL percentiles derived from sNfL
concentrations determined in a large group of healthy indi-
viduals using the same assay as in this study [30].
Statistical analyses were performed with R, version 3.6.2
(association analyses, calculation of effect size measures);
Stata statistics software (Release 15, StataCorp LLC, Col-
lege Station, TX, USA; testing the proportional hazards as-
sumption for Cox regression); and IBM SPSS statistics
software, version 25 (IBM, Armonk, NY, USA; all other
statistics). Figures were created with GraphPad Prism, ver-
sion 8.2.1 (GraphPad Software, San Diego, CA, USA; Fig.
2); IBM SPSS (Fig. 5); and R (all other figures).
P values < 0.05 were considered significant. Due to the
exploratory character of this study, no correction for




Baseline demographic and clinical findings as well as
sGFAP and sNfL values of AQP4-IgG+ and MOG-IgG+
patients and of HC are summarized in Table 1. Patients
with AQP4-IgG+ NMOSD were on average 8 years older
than HC. Only 1 of 33 (3 %) patients with AQP4-IgG+
NMOSD and 2 of 16 (13 %) MOG-IgG+ patients had en-
countered an attack within ≤ 90 days before the baseline
visit. Thus, the vast majority of AQP4-IgG+ and MOG-
IgG+ patients was in clinical remission at study inclusion
with a median (interquartile range [IQR]) time since last
attack of 26 (11–56) months in AQP4-IgG+ patients and
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8 (4–24) months in MOG-IgG+ patients. The majority
of AQP4-IgG+ (88 %) and MOG-IgG+ (75 %) patients
was treated with immunotherapies at study baseline.
Association of sGFAP and sNfL with age and gender
While higher sGFAP was associated with higher age in pa-
tients with AQP4-IgG+ NMOSD (SES = 0.042, p = 0.002),
higher sGFAP was not significantly associated with higher age
in MOG-IgG+ patients (SES = 0.027, p = 0.12) and HC (SES
= 0.02, p = 0.14; interaction effect sGFAP by group ηp
2 = 0.02,
p = 0.48; Fig. 1a). In contrast, higher sNfL was strongly associ-
ated with higher age in AQP4-IgG+ patients (SES = 0.06, p <
0.0001), MOG-IgG+ patients (SES = 0.061, p = 0.0005), and
HC (SES = 0.056, p = 0.0001; interaction effect sNfL by group
ηp
2 < 0.01, p = 0.96; Fig. 1b). Given the association of sGFAP
and sNfL with age, all subsequent linear models and Cox re-
gression analyses were adjusted for age.
There were no relevant differences in median
sGFAP and sNfL between female and male HC
(sGFAP: 67.8 vs. 67.5 pg/ml, p = 0.96; sNfL: 20.0 vs.
18.4 pg/ml, p = 0.93) and MOG-IgG+ patients
(sGFAP: 92.2 vs. 64.1 pg/ml, p = 0.39; sNfL: 23.1 vs.
30.6 pg/ml, p = 0.66). sGFAP and sNfL were higher
in male (sGFAP: 329.0 pg/ml; sNfL: 73.8 than female
(sGFAP: 105.5 pg/ml, p = 0.17; sNfL: 21.1 pg/ml, p =
0.02) patients with AQP4-IgG+ NMOSD, but these
evaluations were limited by the small number of male
patients with AQP4-IgG+ NMOSD (n = 3).
Baseline sGFAP and sNfL in patients with AQP4-IgG+
NMOSD, MOG-IgG+ patients, and healthy controls
Median sGFAP levels were non-significantly higher in
AQP4-IgG+ patients with NMOSD (109.2 pg/ml) than in
MOG-IgG+ patients (81.1 pg/ml; p = 0.83) and HC (67.7
Table 1 Baseline demographic and clinical findings of AQP4-IgG+ patients, MOG-IgG+ patients and healthy controls




Number, n 33 16b 38 – –
age, years, mean (SD) 50 (14) 46 (15) 42 (13) 0.27 0.60
Female/male, n/n (% female) 30/3 (91) 10/6 (63) 31/7 (82) 0.71 0.27
Time from disease onset to
baseline visit, months, median
(IQR)
79 (52–108) 50 (10–148) n.a. 0.04 –
Time from last attack prior to
baseline visit to baseline visit,
months, median (IQR)
26 (11–56) 8 (4–24) n.a. 0.53 –
≥ 1 attack during previous year,
n (%)
11 (33) 11 (69) n.a. 0.76 –
Type of last attack, n (%)c 0.65 –
Optic neuritis 12 (36) 10 (63) n.a.
Myelitis 19 (58) 6 (37) n.a.
Brainstem encephalitis 1 (3) 0 (0) n.a.
EDSS, median (IQR) 4.0 (2.0–5.0) 2.5 (2.0–3.0) n.a. 0.63 –
MSFC, mean (SD) − 0.03 (0.69) 0.25 (0.58) n.a. 0.44 –
9-HPT score, mean (SD) 0.0484 (0.0084) 0.0483 (0.0084) n.a. 0.01 –
T25-FW, s, median (IQR) 5.3 (4.2– 6.2) 4.1 (3.1– 4.9) n.a. 0.92 –
PASAT, median (IQR) 51 (33– 55) 54 (42– 58) n.a. 0.31 –
Immunotherapy, n (%) No: 4 (12) Any: 29 (88) No: 4 (25) Any: 12 (75) n.a. 0.34 –
RTX: 20 (61) AZA: 6 (18) RTX: 8 (50) AZA: 1 (6) n.a. – –
MMF: 1 (3) BEL: 1 (3) TCZ: 1 (3) MMF: 1 (6) GLC: 2 (13) n.a. – –
sGFAP (pg/ml), median (IQR) 109.2 (63.1– 154.8) 81.1 (58.2–116.9) 67.7 (56.6–90.7) 0.03 0.86
sNfL (pg/ml), median (IQR) 21.9 (16.6–41.4) 26.6 (15.9– 43.7) 19.2 (13.7– 29.4) 0.23 0.45
aIn all MOG-IgG+ patients, presence of MOG-IgG+ was confirmed in at least two different assays
bOf the 16 MOG-IgG+ patients, 4 met the Wingerchuk 2015 criteria for AQP4-IgG- NMOSD [7]
cOne AQP4-IgG+ patient had sudden-onset gait impairment as leading symptom at last attack, not clearly attributable to either a brainstem or a myelon lesion
9-HPT 9-Hole Peg Test, AQP4-IgG aquaporin-4 immunoglobulin G, AZA azathioprine, BEL belimumab, EDSS Expanded Disability Status Scale, GLC
glucocorticosteroids, IQR inter quartile range, MMF mycophenolate mofetil, MOG-IgG myelin oligodendrocyte protein immunoglobulin G, MSFC multiple sclerosis
functional composite, n number, n.a. not applicable, NMOSD neuromyelitis optica spectrum disorder, PASAT paced auditory serial addition test, RTX rituximab, s
seconds, SD standard deviation, sGFAP serum glial fibrillary acidic protein, SMD standardized mean difference, sNfL serum neurofilament light chain protein, T25-
FW timed 25-foot walk, TCZ tocilizumab
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Fig. 1 Association of sGFAP and sNfL with age. Association of sGFAP a and sNfL b with age of patients with AQP4-IgG+ NMOSD (n = 33), MOG-IgG+ patients
(n = 16), and healthy controls (n = 38). Results of linear models using log-transformed values of sGFAP and sNfL are shown below the plots. AQP4-IgG
aquaporin-4 immunoglobulin G, β regression coefficient, CI confidence interval, effect size standardized effect size, MOG-IgGmyelin oligodendrocyte protein
immunoglobulin G, NMOSD neuromyelitis optica spectrum disorder, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein
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pg/ml; p = 0.07; Fig. 2a, Table 1). sNfL did not substan-
tially differ between patients with AQP4-IgG+ NMOSD
(21.9 pg/ml), MOG-IgG+ patients (26.6 pg/ml, p = 0.25),
and HC (19.2 pg/ml, p = 0.69; Fig. 2b, Table 1).
Association of sGFAP and sNfL with clinical disability
scores at baseline
We next evaluated whether sGFAP and sNFL are associ-
ated with widely used clinical disability scores, i.e., the
EDSS and the MSFC, in AQP4-IgG+ as compared to
MOG-IgG+ patients. Remarkably, higher sGFAP was
strongly associated with a worse EDSS score in patients
with AQP4-IgG+ NMOSD (SES = 1.30, p = 0.007), but
not MOG-IgG+ patients (SES = − 0.35, p = 0.59; inter-
action effect of sGFAP by group ηp
2 = 0.10, p = 0.04;
Fig. 3a, Table 2). There also was a non-significant associ-
ation of higher sNfL with a worse EDSS score in AQP4-
IgG+ (SES = 1.09, p = 0.15), but not MOG-IgG+ patients
(SES = − 0.29, p = 0.69; interaction effect of sNfL by
group ηp
2 = 0.06, p = 0.11; Fig. 3b, Table 2).
Likewise, higher sGFAP was associated with a worse
MSFC score in patients with AQP4-IgG+ NMOSD (SES =
− 1.28, p = 0.01), but not MOG-IgG+ patients (SES = 0.76,
p = 0.33; interaction effect of sGFAP by group ηp
2 = 0.14,
p = 0.03; Table 2). There also was a non-significant associ-
ation of higher sNfL with a worse MSFC score in AQP4-
IgG+ (SES = − 1.75, p = 0.06), but not in MOG-IgG+ pa-
tients (SES = − 0.37, p = 0.67; interaction effect of sNfL by
group ηp
2 = 0.05, p = 0.20; Table 2).
Analyses of the associations of sGFAP and sNfL with
single components of the MSFC in AQP4-IgG+ and
MOG-IgG+ patients showed that higher sGFAP was as-
sociated with worse performance in the 9-HPT in
AQP4-IgG+ (SES = − 1.03, p = 0.03), but not MOG-IgG+
patients (SES = 0.65, p = 0.32; interaction effect of
sGFAP by group ηp
2 = 0.11, p = 0.04). Higher sNfL was
only non-significantly associated with worse 9-HPT in
AQP4-IgG+ (SES = − 0.82, p = 0.28), but not MOG-IgG+
patients (SES = − 0.47, p = 0.56; interaction effect of
sNfL by group ηp
2 < 0.01, p = 0.7; Table 2). Further-
more, higher sGFAP (SES = − 1.00, p = 0.045) and also
sNfL (SES = − 1.86, p = 0.03) were associated with a
worse PASAT score in AQP4-IgG+ patients with
NMOSD. In contrast, neither sGFAP (SES = 0.21, p =
0.78) nor sNfL (SES = 0.44, p = 0.61) were associated
with the PASAT score in MOG-IgG+ patients. Except
for a non-significant positive association of sNfL with
the T25-FW in MOG-IgG+ patients (SES = 0.89, p =
0.27), sGFAP or sNfL did not show any associations with
the T25-FW in AQP4-IgG+ and MOG-IgG+ patients
(Table 2).
When comparing AQP4-IgG+ patients with
NMOSD treated (n = 29) or not (n = 4) with im-
munotherapy at baseline, median (IQR) sGFAP (101.8
[63.1–154.8] vs. 139.1 [67.5–157.5] pg/ml, p = 0.86)
and sNfL levels (22.3 [16.0–41.4] vs. 20.1 [18.0–52.9]
pg/ml, p = 0.48) did not significantly differ. In pa-
tients with AQP4-IgG+ NMOSD, neither sGFAP (SES
= 0.35, p = 0.48) nor sNfL (SES = 0.14, p = 0.67)
were associated with time on current immunotherapy.
Because sGFAP and sNfL did not significantly differ
in treated and untreated patients with AQP4-IgG+
NMOSD and given the low number of untreated
AQP4-IgG+ patients (n = 4), we refrained from fur-
ther comparative analyses of treated and untreated
patients.
Fig. 2 sGFAP and sNfL in patients with AQP4-IgG+ NMOSD, MOG-IgG+ patients, and healthy controls. Baseline sGFAP a and sNfL b of patients
with AQP4-IgG+ NMOSD (n = 33), MOG-IgG+ patients (n = 16), and healthy controls (n = 38). Bars indicate median and interquartile range. AQP4-
IgG aquaporin-4 immunoglobulin G, MOG-IgG myelin oligodendrocyte protein immunoglobulin G, NMOSD neuromyelitis optica spectrum
disorder, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein
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Fig. 3 (See legend on next page.)
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sGFAP, sNfL, and clinical disability scores on follow-up
Clinical follow-up data as well as sGFAP and sNfL
values were available from 24 patients with AQP4-
IgG+ NMOSD at 1 year (IQR 12–14 months) after
the baseline visit. In these patients, median (IQR)
sGFAP and sNfL showed no substantial differences
between baseline (median [IQR] sGFAP = 89.5 [54.1–
144.9] pg/ml; sNfL = 21.1 [16.0–42.4] pg/ml) and
follow-up (sGFAP = 89.9 [57.8–148.3] pg/ml, p =
0.41; sNfL = 21.7 [14.7–41.5] pg/ml, p = 0.67). In
addition, there were no significant differences in pa-
rameters of clinical disability (EDSS, MSFC, 9-HPT,
PASAT, T25-FW) between baseline and 1-year
follow-up (data not shown). Given the absence of
substantial changes of sGFAP and sNfL values as well
as of clinical disability parameters between baseline
and 1-year follow-up, we refrained from analyses
correlating baseline sGFAP and sNFL with clinical
disability scores on follow-up and from analyses cor-
relating changes of sGFAP and sNFL between base-
line and follow-up with clinical disability scores.
Furthermore, as only 3 of the 24 patients of whom
baseline and follow-up sGFAP and sNfL values were
available had one (2 patients) or two (1 patient) at-
tacks between baseline and one year follow-up, we
refrained from analyses correlating baseline and follow-up
sGFAP and sNfL levels with intercurrent attacks.
Association between sGFAP and sNfL at baseline and
follow-up
Baseline sGFAP was clearly positively associated with
baseline sNfL in patients with AQP4-IgG+ NMOSD (SES
= 2.24, p = 0.001), but not in MOG-IgG+ patients (SES =
0.15, p = 0.83). In HC, baseline sGFAP and sNfL showed a
(See figure on previous page.)
Fig. 3 Association of sGFAP and sNfL with the EDSS. Association of sGFAP a and sNfL b with the Expanded Disability Status Scale (EDSS) score in AQP4-IgG+
(n = 33) and MOG-IgG+ (n = 16) patients. Results of linear models using log-transformed sGFAP and sNfL values adjusted for age and log-transformed time
since last attack are shown below the plots. AQP4-IgG aquaporin-4 immunoglobulin G, β regression coefficient, CI confidence interval, effect size standardized
effect size, MOG-IgGmyelin oligodendrocyte protein immunoglobulin G, NMOSD neuromyelitis optica spectrum disorder, sGFAP serum glial fibrillary acidic
protein, sNfL serum neurofilament light chain protein














β (95% CI) p
EDSSa AQP4-IgG+ (33) 0.10, p = 0.04 1.30 1.78 (0.52–3.04) 0.007 0.06, p = 0.11 1.09 1.58 (− 0.58–3.75) 0.15
MOG-IgG+ (16) − 0.48 − 0.52 (− 2.26–1.30) 0.59 − 0.29 − 0.43 (− 2.55–1.70) 0.69
MSFCa AQP4-IgG+ (25) 0.14, p = 0.03 − 1.28 − 0.73
(− 1.30 to − 0.16)
0.01 0.05, p = 0.20 − 1.75 − 1.05
(− 2.13−0.03)
0.06
MOG-IgG+ (12) 0.76 0.43 (− 0.46–1.32) 0.33 − 0.37 − 0.22 (− 1.26–0.82) 0.67
9-HPTa AQP4-IgG+ (32) 0.11, p = 0.04 − 1.03 − 0.007
(− 0.013 to − 0.001)
0.03 < 0.01,
p = 0.70
− 0.82 − 0.006
(− 0.017–0.005)
0.28
MOG-IgG+ (14) 0.65 0.004 (− 0.004–0.013) 0.32 − 0.47 − 0.003
(− 0.015–0.008)
0.56
PASATa AQP4-IgG+ (27) 0.05, p = 0.19 − 1.00 − 12.7 (− 25.1 to − 0.3) 0.045 0.13, p = 0.03 − 1.86 − 23.0
(− 43.7 to − 2.4)
0.03
MOG-IgG+ (13) 0.21 2.7 (− 17.0–22.4) 0.78 0.44 5.5 (− 15.9–26.9) 0.61
T25-FWb AQP4-IgG+ (30) 0.01, p = 0.61 0.19 0.027 (− 0.105–0.158) 0.69 0.01, p = 0.54 0.31 0.043 (− 0.179–0.265) 0.70
MOG-IgG+ (14) − 0.21 − 0.029 (− 0.212–0.154) 0.75 0.89 0.122 (− 0.099–0.343) 0.27
aLinear model using log-transformed sGFAP or sNfL values, including age as well as the log-transformed interval since the last attack as covariates. Furthermore,
an interaction term of baseline sGFAP or sNFL (log-transformed) and group was included to assess the statistical significance of inter group differences
bLinear model using log-transformed sGFAP or sNfL and log-transformed T25-FW values, including age as well as the log-transformed interval since the last attack
as covariates. Furthermore, an interaction term of baseline sGFAP or sNFL (log-transformed) and group was included to assess the statistical significance of inter
group differences
Note that a higher EDSS score indicates a worse functional status, whereas a higher MSFC score indicates a better functional status. The EDSS [23] is the most
common score to rate global neurological dysfunction secondary to MS and NMOSD. The MSFC [24] is a more complex, multidimensional scoring system for
neurological impairment in MS and NMOSD, which consists of three components. These components, which may each be used individually as well, are the 9-HPT,
PASAT, and T25-FW. The 9-HPT assesses upper extremity function and dexterity. PASAT, in rating the processing speed of auditory input and calculation ability,
quantifies cognitive impairment. T25-FW addresses lower extremity function based on walking speed
9-HPT 9-hole peg test, AQP4-IgG aquaporin-4 immunoglobulin G, β regression coefficient, CI confidence interval, ηρ
2 partial eta-squared, EDSS expanded disability
status scale, MOG-IgG myelin oligodendrocyte protein immunoglobulin G, MSFC multiple sclerosis functional composite, n number, NMOSD neuromyelitis optica
spectrum disorder, PASAT paced auditory serial addition test, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein, T25-FW timed
25-foot walk
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Fig. 4 (See legend on next page.)
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non-significant positive association (SES = 1.00, p = 0.06;
interaction effect of sNfL by group ηp
2 = 0.07, p = 0.049;
Fig. 4). Changes in sGFAP and sNfL levels between base-
line and one year (IQR 12–14 months) follow-up were
positively associated in patients with AQP4-IgG+ NMOSD
(SES = 0.13; p < 0.001), but not in MOG-IgG+ patients
(SES = 0.005; p = 0.42; interaction effect of change in sNfL
by group ηp
2 = 0.52, p < 0.0001; Fig. 4).
Association of sGFAP and sNfL with disease duration and
time since last attack
In patients with AQP4-IgG+ NMOSD, baseline sGFAP
was neither associated with time since first manifestation
of disease (SES = 0.18, p = 0.70) nor with time since last
attack (SES = 0.41, p = 0.37; Table 3). In contrast, in pa-
tients with AQP4-IgG+ NMOSD, sNfL was non-
significantly higher the shorter the time since first mani-
festation of the disease (SES = − 1.27, p = 0.08) and the
shorter the time since last attack (SES = − 1.22, p =
0.10).
In MOG-IgG+ patients, higher baseline sGFAP was non-
significantly associated with shorter time since first manifest-
ation of disease (SES = − 0.96, p = 0.14), but baseline sGFAP
was not associated with time since last attack (SES = − 0.47,
p = 0.46; Table 3). The non-significant negative association
of sGFAP with time since first manifestation of disease in
MOG-IgG+ patients should thus be interpreted with caution.
However, in MOG-IgG+ patients, baseline sNfL was higher
the shorter the time since first manifestation of disease (SES
= − 1.99, p = 0.008) and there also was a non-significant as-
sociation of higher baseline sNfL with shorter time since the
last attack (SES = − 0.99, p = 0.17; Table 3).
Association of baseline sGFAP and sNfL with future
attacks in patients with AQP4-IgG+ NMOSD
Data on attacks were available from all patients with
AQP4-IgG+ NMOSD over a median (IQR) observation
period of 51 (36–90) months. Among the 33 AQP4-IgG+
patients, 7 (21%) patients had at least one attack during
the observation period. To evaluate an association of
sGFAP with time to a future attack, patients were di-
vided into “high” vs. ”low” sGFAP groups, using a base-
line sGFAP level of 90 pg/ml, derived from the 75th
percentile of sGFAP in HC (90.7 pg/ml), as cut-off. In
patients with AQP4-IgG+ NMOSD with baseline sGFAP
> 90 pg/ml, the time to a first attack was shorter than in
patients with baseline sGFAP ≤ 90 pg/ml (adjusted haz-
ard ratio [HR] = 11.6, 95% CI = 1.3–105.6, p = 0.03; Fig.
5a). Of note, a similar percentage of patients was treated
with immunotherapies in the “low” (93%) and “high”
(84%, SMD = 0.27, p = 0.45) sGFAP groups. Similar re-
sults were obtained when using a baseline sGFAP value
of 110 pg/ml, derived from the 90th percentile of sGFAP
in HC (109.4 pg/ml), as cut-off (> 110 pg/ml: n = 16, ≤
(See figure on previous page.)
Fig. 4 Associations between sGFAP and sNfL. a Association between log-transformed baseline sGFAP and sNfL in patients with AQP4-IgG+
NMOSD (n = 33), MOG-IgG+ patients (n = 16) and healthy controls (n = 38). b Association between changes in sGFAP (dGFAP) and sNfL (dNfL)
concentrations, i.e., difference between one year and baseline values, in patients with AQP4-IgG+ NMOSD (n = 24) and MOG-IgG+ patients (n =
13). In Fig. 4b, one datapoint of an AQP4-IgG+ patient (dGFAP = 221.1 pg/ml, dNfL = 24.2 pg/ml) is not plotted for better visualization of
datapoints with lower dGFAP, but included in the analyses. Results of linear models using log-transformed sGFAP and sNfL values adjusted for
age and, where applicable (b), log-transformed time since last attack are shown below the plots. AQP4-IgG aquaporin-4 immunoglobulin G, β
regression coefficient, CI confidence interval, dGFAP difference in sGFAP between one year and baseline, dNfL difference in sNfL between 1 year
and baseline, effect size standardized effect size, MOG-IgG myelin oligodendrocyte protein immunoglobulin G, NMOSD neuromyelitis spectrum
disorders, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein





















0.05, p = 0.14 0.18 0.20 (− 0.84–
1.24)





− 0.96 − 1.10 (−
2.58–0.38)





0.03, p = 0.25 0.41 0.46 (− 0.55–
1.47)





-0.47 − 0.53 (−
1.96–0.91)
0.46 − 0.99 − 1.08 (− 2.63–
0.48)
0.17
aLinear models using log-transformed sGFAP and sNfL and time interval values, adjusted for age. Furthermore, an interaction term of baseline sGFAP or sNFL (log-
transformed) and group was included to assess the statistical significance of inter group differences
AQP4-IgG aquaporin-4 immunoglobulin G, β regression coefficient, CI confidence interval, ηρ
2 partial eta-squared, MOG-IgG myelin oligodendrocyte protein
immunoglobulin G, n number, NMOSD neuromyelitis optica spectrum disorders, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain
protein, std. effect size standardized effect size
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110 pg/ml: n = 17, adjusted HR = 26.9, 95% CI = 2.0–
360.8, p = 0.01). Due to the limited size of the MOG-
IgG+ cohort, we refrained from analyses of associations
of sGFAP and sNfL with future attacks in this group.
Based on data from a large HC cohort [30], we used
the 75th age adjusted sNfL percentile to dichotomize pa-
tients with AQP4-IgG+ NMOSD into “high” and ”low”
baseline sNfL groups. The time to a new attack was
similar in AQP4-IgG+ patients with “high” baseline sNfL
compared to those with “low” baseline sNfL values (ad-
justed HR = 0.5, 95% CI = 0.05–5.9, p = 0.60; Fig. 5b).
Again, a similar percentage of patients was treated with
immunotherapies in the “low” (86%) and “high” (91%)
sNfL groups (SMD = 0.14, p = 0.71). Similar results were
obtained when using the 90th age-adjusted sNfL percent-
ile as cut-off (> 90th age-adjusted percentile: n = 5, ≤ 90th
age-adjusted percentile: n = 28, adjusted HR = 9.0, 95%
CI = 0.3–253.2, p = 0.20).
Discussion
The key results of this detailed analysis of sGFAP and
sNfL measured by Simoa in a well-characterized cohort
of AQP4-IgG+ and MOG-IgG+ patients, most of which
were in clinical remission at study baseline, as well as in
HC are (1) sGFAP levels of AQP4-IgG+ patients were
just mildly and not significantly higher than those of
MOG-IgG+ patients and HC, and sNFL levels did not
substantially differ between groups. (2) However, re-
markably, sGFAP was still clearly associated with param-
eters of clinical disability (EDSS, MSFC) in patients with
AQP4-IgG+ NMOSD. In contrast, no associations of
sGFAP with parameters of clinical disability were ob-
served in MOG-IgG+ patients. (3) While baseline sGFAP
and sNfL were positively associated in patients with
AQP4-IgG+ NMOSD, but not MOG-IgG+ patients, asso-
ciations of sNFL with parameters of clinical disability in
patients with AQP4-IgG+ NMOSD were weaker and less
consistent than those of sGFAP. (4) In this prospective
cohort with a median observation period of 4.25 years,
higher baseline sGFAP, but not sNfL, was associated
with a shorter time to a future attack in patients with
AQP4-IgG+ NMOSD.
The median sGFAP levels of the 33 patients with
AQP4-IgG+ NMOSD measured in this work (109.2 pg/
ml) were lower than those reported by Watanabe et al.
(207.7 pg/ml, n = 33 patients with NMOSD, 30 of which
were AQP4-IgG+) and Kim et al. (123.1 pg/ml, n = 33
patients with AQP4-IgG+ NMOSD) [20, 21]. One may
argue that this could be related to differences between
Asian and Caucasian patients with AQP4-IgG+ NMOSD
investigated in the previous studies and the present
work. However, while serum samples were collected at a
median of about 4 months after the last attack in both
the studies of Watanabe et al. and Kim et al. [20, 21],
the median interval between blood withdrawal and last
attack in the AQP4-IgG+ patients studied in this work
was 26 months. Both previous studies found higher
sGFAP in patients with a recent attack than in patients
Fig. 5 Association of baseline sGFAP and sNfL with time to a future
attack in patients with AQP4-IgG+ NMOSD. a Patients with AQP4-IgG+
NMOSD (n = 33) were grouped into those with “high” and “low”
baseline sGFAP values, using a sGFAP value of 90 pg/ml, derived from
75th sGFAP percentile in healthy controls (90.7 pg/ml), as cut-off. The
survival curves show the adjusted cumulative attack free survival
probability in patients with baseline sGFAP ≤ or > 90 pg/ml. b Patients
with AQP4-IgG+ NMOSD (n = 33) were grouped into those with “high”
and “low” baseline sNfL values using the 75th age-adjusted percentile
as cut-off. The survival curves show the adjusted cumulative attack free
survival probability in patients with baseline sNfL ≤ or > 75th age-
adjusted percentile. Hazard ratios (HR) with 95% confidence intervals
(CI) calculated by Cox regression analyses adjusted for age and time
since last attack prior to study inclusion and p values are indicated. The
number of patients at risk for an attack in each group is indicated
below the graphs. CI confidence interval, NMOSD neuromyelitis optica
spectrum disorder, HR hazard ratio, sGFAP serum glial fibrillary acidic
protein, sNfL serum neurofilament light chain protein
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in remission [20, 21]. The lower sGFAP levels seen in
our work may thus very likely be explained by the longer
interval between the last attack and serum withdrawal in
the present study. Indeed, serial blood withdrawals in
patients with mild to moderate traumatic brain injury
showed that sGFAP peaks at 20 h after injury and there-
after declines over 72 h, indicating a relatively short half-
life of sGFAP [31]. The lack of an association of sGFAP
with time to last attack in patients with AQP4-IgG+
(Table 3) and the only mild elevation of sGFAP in pa-
tients with AQP4-IgG+ NMOSD as compared to MOG-
IgG+ patients and HC (Fig. 2, Table 1) may therefore
likewise be related to the long interval between the last
attack and blood withdrawal. In contrast, longitudinal
studies of patients with multiple sclerosis, traumatic
brain injury, and stroke have shown that after increasing
over days sNfL levels can remain elevated over months
[32], which appears consistent with the associations of
higher sNfL with shorter time to first manifestation of
disease and shorter time to last attack in patients with
AQP4-IgG+ NMOSD and MOG-IgG+ patients observed
in the present work (Table 3). Altogether, our findings
underscore a critical role of the timepoint of sGFAP de-
terminations relative to a last attack when interpreting
sGFAP values in patients with AQP4-IgG+ NMOSD.
Due to the low number of untreated AQP4-IgG+ patients
with NMOSD included in our study, the absence of differ-
ences between sGFAP levels in treated and untreated pa-
tients with AQP4-IgG+ NMOSD should be regarded with
caution. This study was not designed to detect influences of
treatments on sGFAP levels and cannot exclude that differ-
ences in sGFAP may be detectable in larger studies specific-
ally addressing the association of sGFAP with treatment
status of patients with AQP4-IgG+ NMOSD.
The just mildly elevated sGFAP levels of patients with
AQP4-IgG+ NMOSD in clinical remission do not sug-
gest that sGFAP might be a useful diagnostic biomarker
in this situation. However, our study confirms previously
observed associations of GFAP in serum [20, 21] and
CSF [13, 15] with the EDSS and additionally shows asso-
ciations of sGFAP with the MSFC and some of its com-
ponents (9-HPT, PASAT) in AQP4-IgG+ patients with
NMOSD (Fig. 3, Table 2), suggesting a potential role for
sGFAP as biomarker for disease severity in patients with
AQP4-IgG+ NMOSD. Of note, the robust associations of
higher sGFAP with worse clinical disability scores in the
AQP4-IgG+ patients with NMOSD in clinical remission
included in our study are rather remarkable, as they ap-
pear unlikely to be due to residual sGFAP elevations
after a prior attack. While further research will be re-
quired to clarify the pathophysiological correlate of this
finding, we propose two hypothetical explanations: First,
sGFAP levels in AQP4-IgG+ patients with NMOSD in
clinical remission could reflect ongoing subclinical
astrocytic damage with consecutive GFAP release, pos-
sibly due to a persistent low level smoldering inflamma-
tion. Second, sGFAP levels in AQP4-IgG+ patients with
NMOSD in clinical remission could reflect continuing
astrocyte degeneration following an acute attack.
The association of higher sGFAP levels with a shorter
time to a future attack in patients with AQP4-IgG+
NMOSD is an important finding of this study, suggest-
ing that, if reproduced in independent prospective co-
horts, sGFAP could be a biomarker for future disease
activity in patients with AQP4-IgG+ NMOSD in clinical
remission. However, while the sGFAP cut-off (90 pg/ml)
established in the present work, which was based on the
75th percentile of sGFAP in HC, may prove valid in pa-
tients with AQP4-IgG+ NMOSD with a long interval to
the last attack, the generalizability of this cut-off needs
to be further explored, and different cut-offs may apply
to more active AQP4-IgG+ patient populations with a
shorter interval to the last attack.
sNfL was not substantially increased in the investigated
patient groups and, except for a negative association with
the PASAT, only showed non-significant associations with
disability markers in patients with AQP4-IgG+ NMOSD
(Table 2). Furthermore, sNfL was not associated with future
disease activity in AQP4-IgG+ NMOSD (Fig. 5). These find-
ings suggest that sGFAP is more specifically and more
strongly associated with the disease process of AQP4-IgG+
NMOSD than sNfL, which complies well with the patho-
physiological concept of AQP4-IgG+ NMOSD being an
antibody-mediated astrocytopathy [5, 6]. The positive associ-
ations of sGFAP and sNfL in AQP4-IgG+ NMOSD, but not
MOG-IgG+ patients (Fig. 4), therefore seem compatible with
a scenario in which a primary antibody-mediated astrocyto-
pathy results in secondary neuroaxonal damage. In this sce-
nario, sNfL would only be indirectly linked to the disease
process of AQP4-IgG+ NMOSD, which might explain the
weaker or absent associations of sNfL with clinical disability
parameters and future disease activity in AQP4-IgG+ pa-
tients. Altogether, our present findings rather argue against
a role of sNfL as disease severity or prognostic biomarker in
AQP4-IgG+ NMOSD in phases of clinical remission.
From a clinical practice point of view, blood-based
biomarkers would be particularly useful in patients with
AQP4-IgG+ NMOSD in clinical remission, where deci-
sions on continuation, escalation or de-escalation of re-
lapse preventing therapies have to be made, which
sometimes can be clinically challenging. The associations
of sGFAP with clinical disability and the potential prog-
nostic value of sGFAP in patients with AQP4-IgG+
NMOSD in phases of clinical remission seen in the
present study overall suggest that further investigations
on the value of sGFAP measurements in independent
cohorts of patients with AQP4-IgG+ NMOSD in phases
of clinical remission are warranted. Such studies may
Schindler et al. Journal of Neuroinflammation          (2021) 18:105 Page 12 of 14
also evaluate the potential role of sGFAP to guide treat-
ment decisions in patients with AQP4-IgG+ NMOSD.
Advantages of this study are its prospective design
with a long observation period and the highly standard-
ized acquisition of serum samples and comprehensive
clinical data. Nevertheless, although the number of pa-
tients with AQP4-IgG+ NMOSD analyzed in this work
was similar to that of previous studies [20, 21], one limi-
tation of this monocentric work is the number of AQP4-
IgG+ and MOG-IgG+ patients, which both are rare dis-
ease entities, available for analysis.
Conclusions
This study suggests a potential role for sGFAP as biomarker
for disease severity and future disease activity in patients
with AQP4-IgG+ NMOSD in phases of clinical remission.
This is consistent with the pathophysiological concept of
AQP4-IgG+ NMOSD being an immune-mediated astrocyto-
pathy. The potential relevance of sGFAP as disease severity
and prognostic biomarker in AQP4-IgG+ NMOSD thus
warrants to be further explored in independent cohorts of
AQP4-IgG+ patients with NMOSD.
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